ERBB2 and breast cancer: Clinically, BC is classified mainly by immuno-histochemistry (IHC) according to the estrogen- and progesterone receptor status, the increased expression of the epidermal growth factor receptor HER2/NEU (erbb2), and the proliferation rate as determined by the Ki-67 status.